83 related articles for article (PubMed ID: 3332914)
1. A double-blind evaluation of ciladopa in Parkinson's disease.
Weiner WJ; Factor SA; Sanchez-Ramos J; Berger J
Mov Disord; 1987; 2(3):211-7. PubMed ID: 3332914
[TBL] [Abstract][Full Text] [Related]
2. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.
Olanow CW; Fahn S; Muenter M; Klawans H; Hurtig H; Stern M; Shoulson I; Kurlan R; Grimes JD; Jankovic J
Mov Disord; 1994 Jan; 9(1):40-7. PubMed ID: 8139604
[TBL] [Abstract][Full Text] [Related]
3. Parallel double-blind study of pergolide in Parkinson's disease.
Jankovic J; Orman J
Adv Neurol; 1987; 45():551-4. PubMed ID: 3548265
[No Abstract] [Full Text] [Related]
4. Controlled-release carbidopa-levodopa (Sinemet) in combination with standard Sinemet in advanced Parkinson's disease.
Mark MH; Sage JI
Ann Clin Lab Sci; 1989; 19(2):101-6. PubMed ID: 2665626
[TBL] [Abstract][Full Text] [Related]
5. Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease.
Olanow CW; Alberts MJ
Adv Neurol; 1987; 45():555-60. PubMed ID: 3548266
[No Abstract] [Full Text] [Related]
6. Trial of Sinemet CR4 in patients with Parkinson's disease.
Anderson TJ; Ewer TC; Gilchrist NL; Donaldson IM
N Z Med J; 1992 Mar; 105(929):81-2. PubMed ID: 1545941
[TBL] [Abstract][Full Text] [Related]
7. The Sydney multicentre study of Parkinson's disease. The first 18 months.
Hely MA; Morris JG; Rail D; O'Sullivan DJ; Williamson PM; Genge S; Reid WG; Broe GA
Med J Aust; 1987 Feb; 146(4):195-8. PubMed ID: 3553878
[TBL] [Abstract][Full Text] [Related]
8. Double-blind comparison of standard Sinemet and Sinemet CR in patients with mild-to-moderate Parkinson's disease.
Feldman RG; Mosbach PA; Kelly MR; Thomas CA; Saint Hilaire MH
Neurology; 1989 Nov; 39(11 Suppl 2):96-101; discussion 105. PubMed ID: 2685655
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy of controlled-release carbidopa/levodopa in patients with advanced Parkinson's disease.
Mark MH; Sage JI
Ann Clin Lab Sci; 1989; 19(6):415-21. PubMed ID: 2690730
[TBL] [Abstract][Full Text] [Related]
10. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J
Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
[TBL] [Abstract][Full Text] [Related]
11. Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.
Gawel M; Riopelle R; Libman I; Bouchard S
Adv Neurol; 1987; 45():535-8. PubMed ID: 3548263
[No Abstract] [Full Text] [Related]
12. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
García de Yébenes J; Mateo D; Pino MA; Cordero M; Pastor M; Chacón J; Morales B; Sánchez V; Mena MA; Giménez Roldán S
Neurologia; 1997 Apr; 12(4):145-56. PubMed ID: 9235023
[TBL] [Abstract][Full Text] [Related]
13. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
14. Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson's disease.
Savery F
Dis Nerv Syst; 1977 Aug; 38(8):605-8. PubMed ID: 328244
[TBL] [Abstract][Full Text] [Related]
15. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.
Rascol O; Fabre N; Blin O; Poulik J; Sabatini U; Senard JM; Ané M; Montastruc JL; Rascol A
Mov Disord; 1994 Jul; 9(4):437-40. PubMed ID: 7969211
[TBL] [Abstract][Full Text] [Related]
16. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study.
Murata M; Hasegawa K; Kanazawa I;
Neurology; 2007 Jan; 68(1):45-50. PubMed ID: 17200492
[TBL] [Abstract][Full Text] [Related]
17. Effect of ciladopa on Parkinson's disease: a preliminary report.
Weiner WJ; Berger JR
Adv Neurol; 1987; 45():583-6. PubMed ID: 3548268
[No Abstract] [Full Text] [Related]
18. CV 205-502: safety, tolerance to, and efficacy of increasing doses in patients with Parkinson's disease in a double-blind, placebo crossover study.
Olanow CW; Werner EG; Gauger LL
Clin Neuropharmacol; 1989 Dec; 12(6):490-7. PubMed ID: 2575014
[TBL] [Abstract][Full Text] [Related]
19. Double-blind trial of R-(-)-deprenyl for the "on-off" effect complicating Parkinson's disease.
Golbe LI; Duvoisin RC
J Neural Transm Suppl; 1987; 25():123-9. PubMed ID: 3123598
[TBL] [Abstract][Full Text] [Related]
20. Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
Cedarbaum JM; Hoey M; Kutt H; McDowell FH
Clin Neuropharmacol; 1988 Apr; 11(2):168-73. PubMed ID: 3378225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
